Oral News and Research

RSS

Cardiovascular disease in COVID-19

The current COVID-19 pandemic is a primarily respiratory illness, manifesting with severe hypoxia and often progressing to acute respiratory distress syndrome (ARDS) and death. However, it is also known to be linked to a wide range of cardiovascular (CV) manifestations that are associated with a very poor prognosis.

13 Aug 2020

Updated clinical practice guidelines for managing mucositis published

Updated clinical practice guidelines for managing mucositis, a very common and often debilitating complication of cancer therapy, was recently published in the journal Cancer.

11 Aug 2020

SARS-CoV-2 infection and transmission possible in North American deer mice

The current COVID-19 pandemic began as a zoonosis in China, at the end of 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel betacoronavirus with significant similarity to an earlier virus of the same family.

11 Aug 2020

Novel coronavirus does not directly damage taste bud cells, UGA study shows

A new study from the Regenerative Bioscience Center at the University of Georgia is the first to suggest that COVID-19 does not directly damage taste bud cells.

10 Aug 2020

Mouthwashes could lower the transmission of SARS-CoV-2

Sars-Cov-2 viruses can be inactivated using certain commercially available mouthwashes. This was demonstrated in cell culture experiments by virologists from Ruhr-Universität Bochum together with colleagues from Jena, Ulm, Duisburg-Essen, Nuremberg and Bremen. High viral loads can be detected in the oral cavity and throat of some Covid-19 patients.

10 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020

New platform shows potential to generate most effective vaccines with fewest side effects

The ongoing COVID-19 pandemic is shining a bright spotlight on vaccine development. As numerous vaccines race through clinical trials, physicians and researchers continue to work on developing new vaccine technologies to generate the most effective vaccines with the fewest side effects.

7 Aug 2020

FDA approves first oral drug for treatment of spinal muscular atrophy

The U.S. Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

7 Aug 2020

New test can pinpoint which people with gonorrhea can be cured with ciprofloxacin

A test designed by UCLA researchers can pinpoint which people with gonorrhea will respond successfully to the inexpensive oral antibiotic ciprofloxacin, which had previously been sidelined over concerns the bacterium that causes the infection was becoming resistant to it.

7 Aug 2020

UArizona researcher aims to deliver statins effectively into the brain of stroke patients

Every year in the United States, about 800,000 people experience a stroke. Many are left with neurological complications such as paralysis on one side of the body, speech and language problems, vision issues, behavioral changes, and memory loss.

6 Aug 2020

Will smoking cannabis harm your heart?, yes says AMA

The American Heart Association (AHA), in their statement, has said that smoking cannabis (marijuana) could be harmful to the heart. This new stand on smoking weed was published this week in the journal Circulation. The announcement is released as an article titled, “Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association.”

6 Aug 2020

Non-hormonal therapy found to be effective for menopause-associated symptoms

A non-hormonal therapy to treat hot flashes and other symptoms associated with menopause was found to be effective in a recent clinical trial, according to a published study by a team of researchers including faculty from the University of Colorado School of Medicine.

6 Aug 2020

Cats susceptible to and potential reservoirs for novel coronavirus

The study published on the preprint server bioRxiv in August 2020 shows that this is indeed taking place, with pet cats being infected and passing on the infection to contacts. It also offers the chance to see how the disease progresses in a susceptible host.

6 Aug 2020

SARS-CoV-2 may not be targeting taste bud cells

An intriguing early symptom among some COVID-19 patients is the loss of the sense of smell and/or taste, which has led to the suspicion that the virus that causes the illness, SARS-CoV-2, could be targeting taste buds.

5 Aug 2020

Evidence for antibody longevity in COVID-19 patients

A study led by researchers at the University of Toronto, Canada, has found evidence that immunoglobulin G (IgG) antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are sustained for at least three months.

5 Aug 2020

Estrogen modestly protective against COVID-19?

Almost from the beginning, scientists have been struck by the disproportionately higher numbers of men and older adults who have developed severe COVID-19 disease compared to younger individuals and women. Prior research has shown that in 37 of the 38 countries from which sex-stratified data was available, males were at a higher risk of death. Also, post-menopausal women are at increased risk of severe COVID-19. However, the biological underpinnings of this have been less visible.

4 Aug 2020

Asthma drugs improve performance in healthy non-asthmatic subjects

Popular asthma control drugs β2-agonists such as Albuterol, Formoterol, Terbutaline, etc. that are used as inhalers by millions of asthmatics around the world could have power and stamina enhancing properties in sportspersons, finds a new study.

3 Aug 2020

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

In a groundbreaking bioRxiv study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using both an S protein sequence optimized for cell surface expression and a conserved nucleocapsid antigen designed to be transported to the endosomal subcellular compartment.

2 Aug 2020

FDA approves CBD oral solution for treatment of seizures related to tuberous sclerosis complex

Today, the U.S. Food and Drug Administration approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.

31 Jul 2020